Cytodyn INC 10-Q quarterly reports

CytoDyn Inc. files its Q3 2026 Form 10-Q, detailing financial performance, operational updates, and ongoing legal matters.

CytoDyn Inc. reported a significant net loss for Q2 2026, settled a major class-action lawsuit, and disclosed substantial doubt about its ability to continue as a going concern.

CytoDyn Inc. reported a net loss of $5.54 million for the quarter ended August 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern.

CytoDyn Inc. reports a net income of $9.7 million for the nine months ended February 28, 2025, primarily due to a legal settlement, while facing ongoing legal proceedings and financial uncertainties.

CytoDyn Inc. reports a net income of $14.5 million for the six months ended November 30, 2024, primarily due to a settlement with Amarex, while highlighting ongoing efforts in clinical development of leronlimab.

CytoDyn reports a net income of $19.2 million for the quarter ended August 31, 2024, primarily due to a settlement with Amarex, while also highlighting ongoing financial challenges and the need for additional funding.

CytoDyn Inc. announced its financial results for the third quarter of fiscal year 2024, highlighting the lifting of the clinical hold on leronlimab and ongoing efforts in research and development.

CytoDyn's Q2 2024 report reveals ongoing financial losses, a lifted and then new clinical hold on its HIV program, and efforts to secure additional funding.